Holen Sie sich die Stockscreener-App
13.08
1.51%
-0.20
Handel nachbörslich:
13.34
0.26
+1.99%
Schlusskurs vom Vortag:
$13.28
Offen:
$13.32
24-Stunden-Volumen:
695.24K
Relative Volume:
4.82
Marktkapitalisierung:
$1.67B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+16.68%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.80
$13.70
1-Wochen-Bereich:
$11.60
$13.70
52-Wochen-Spanne:
$11.00
$13.95
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.08 | 1.69B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Goodwin Advises Generate Biomedicines, Inc. On The Closing Of Its $400 Million Initial Public Offering - Mondaq
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines IPO Opens Nasdaq Chapter And Investor Watch Period - simplywall.st
GENB Stock Price, News & Analysis - Stock Titan
Generate Biomedicines, Inc. (GENB) Stock Live Price, Chart & News - CoinCodex
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - Sahm
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - Dealbreaker
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
Generate Biomedicines prices IPO at $16 per share By Investing.com - Investing.com Australia
Generate Biomedicines Shares Plummet After $400 Million Market Debut - WSJ
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
AI-Focused Generate Biomedicines Prices $400M IPO - Law360
Generate Biomedicines, AI-Driven Generative Biology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingView
Generate Biomedicines Share Price Target and Forecast - Investing.com India
Generate Biomedicines stock opens below IPO price in Nasdaq debut By Investing.com - Investing.com South Africa
Generate Biomedicines stock opens below IPO price in Nasdaq debut - Investing.com
Generate Biomedicines Shares Fall After Nasdaq Debut - marketscreener.com
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - AOL.com
Generate Biomedicines-Aktien fallen bei schwachem Nasdaq-Debüt des Arzneimittelentwicklers - TradingView
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer - TradingView
Shares of Generate Biomedicines open at $15 in their Nasdaq debut vs $16 IPO price - marketscreener.com
TSLP still plays well, Generates $400M IPO - BioWorld MedTech
Generate Biomedicines, Inc. share price - Capital.com
AI-driven drug developer nets $400M IPO, matching 2020 record - The Business Journals
Generate’s $400m IPO Adds To Biotech Bounceback - Citeline News & Insights
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Trade Generate Biomedicines, Inc.GENB CFD - Capital.com
Generate:Biomedicines Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Generate:Biomedicines Rings the Opening Bell - Nasdaq
Generate Biomedicines secures $400m IPO in flurry of February listings - Yahoo Finance
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - The Malaysian Reserve
Generate Biomedicines Announces IPO Terms for $400 Million Raise - Intellectia AI
Generate Biomedicines Prices IPO at $20 Per Share to Raise $240 Million - geneonline.com
Drug developer Generate Biomedicines raises $400 million in US IPO - marketscreener.com
Generate caps a strong month for biotech IPOs with $400M offering - BioPharma Dive
AI biotech Generate Biomedicines raises $400M in IPO - Axios
Generate Biomedicines prices IPO at $16 per share - Investing.com
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Es liegen keine Finanzdaten für Generate Biomedicines Inc (GENB) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):